(Q39439865)

12 September 2017

title

Clinical activity and benefit of irinotecan (CPT-11) in patients with colorectal cancer truly resistant to 5-fluorouracil (5-FU). (English)

1 reference

12 September 2017

1 reference

1 reference

1 reference

1 reference

2

1 reference

12 September 2017

E Van Cutsem

1

1 reference

12 September 2017

W W Ten Bokkel Huinink

3

1 reference

12 September 2017

C J Punt

4

1 reference

12 September 2017

C G Alexopoulos

5

1 reference

12 September 2017

L Dirix

6

1 reference

12 September 2017

M Symann

7

1 reference

12 September 2017

G H Blijham

8

1 reference

12 September 2017

P Cholet

9

1 reference

12 September 2017

G Fillet

10

1 reference

12 September 2017

C Van Groeningen

11

1 reference

12 September 2017

J M Vannetzel

12

1 reference

12 September 2017

F Levi

13

1 reference

12 September 2017

G Panagos

14

1 reference

12 September 2017

C Unger

15

1 reference

12 September 2017

J Wils

16

1 reference

12 September 2017

C Cote

17

1 reference

12 September 2017

C Blanc

18

1 reference

12 September 2017

P Hérait

19

1 reference

12 September 2017

H Bleiberg

20

1 reference

12 September 2017

publication date

1 January 1999

1 reference

12 September 2017

number of pages

6

1 reference

European Journal of Cancer

inferred from page(s)

published in

1 reference

12 September 2017

volume

35

1 reference

12 September 2017

issue

1

1 reference

12 September 2017

page(s)

54-59

1 reference

The chemotherapy of colon cancer can no longer be ignored

12 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2898%2900353-0

7 January 2021

Expectancy or primary chemotherapy in patients with advanced asymptomatic colorectal cancer: a randomized trial

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2898%2900353-0

7 January 2021

Randomised comparison of combination chemotherapy plus supportive care with supportive care alone in patients with metastatic colorectal cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2898%2900353-0

7 January 2021

Modulation of fluorouracil by leucovorin in patients with advanced colorectal cancer: evidence in terms of response rate. Advanced Colorectal Cancer Meta-Analysis Project

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2898%2900353-0

7 January 2021

Overview of clinical trials using 5-fluorouracil and leucovorin for the treatment of colorectal cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2898%2900353-0

7 January 2021

Weekly therapy with folinic acid (FA) and high-dose 5-fluorouracil (5-FU) 24-hour infusion in pretreated patients with metastatic colorectal carcinoma. A multicenter study by the Association of Medical Oncology of the German Cancer Society (AIO)

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2898%2900353-0

7 January 2021

Topoisomerase I inhibitors: topotecan and irenotecan

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2898%2900353-0

7 January 2021

CPT-11 (Irinotecan) in the treatment of colorectal cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2898%2900353-0

7 January 2021

Irinotecan is an active agent in untreated patients with metastatic colorectal cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2898%2900353-0

7 January 2021

Phase II trial of irinotecan in patients with progressive or rapidly recurrent colorectal cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2898%2900353-0

7 January 2021

Phase II study of irinotecan in the treatment of advanced colorectal cancer in chemotherapy-naive patients and patients pretreated with fluorouracil-based chemotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2898%2900353-0

7 January 2021

One-sample multiple testing procedure for phase II clinical trials

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2898%2900353-0

7 January 2021

Protracted infusion of 5-FU with weekly low-dose cisplatin as second-line therapy in patients with metastatic colorectal cancer who have failed 5-FU monotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2898%2900353-0

7 January 2021

Phase II study of 5-fluorouracil plus leucovorin and interferon alpha 2b in advanced colorectal cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2898%2900353-0

7 January 2021

Protracted venous infusion 5-fluorouracil and interferon-alpha in advanced and refractory colorectal cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2898%2900353-0

7 January 2021

Continuous infusion fluorouracil/leucovorin and bolus mitomycin-C as a salvage regimen for patients with advanced colorectal cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2898%2900353-0

7 January 2021

Second-line chemotherapy of advanced colorectal cancer with sequential high-dose methotrexate and 5-fluorouracil

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2898%2900353-0

7 January 2021

Salvage chemotherapy in colorectal cancer patients with good performance status and young age after failure of 5-fluorouracil/leucovorin combination

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2898%2900353-0

7 January 2021

Oxaliplatin activity against metastatic colorectal cancer. A phase II study of 5-day continuous venous infusion at circadian rhythm modulated rate

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2898%2900353-0

7 January 2021

Two consecutive phase II studies of oxaliplatin (L-OHP) for treatment of patients with advanced colorectal carcinoma who were resistant to previous treatment with fluoropyrimidines

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2898%2900353-0

7 January 2021

Oxaliplatin with high-dose leucovorin and 5-fluorouracil 48-hour continuous infusion in pretreated metastatic colorectal cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2898%2900353-0

7 January 2021

The relationship between an objective response to chemotherapy and survival in advanced colorectal cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2898%2900353-0

7 January 2021

Quality of life during chemotherapy in patients with symptomatic advanced colorectal cancer. The Nordic Gastrointestinal Tumor Adjuvant Therapy Group.

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2898%2900353-0

7 January 2021

Randomized comparison of two schedules of fluorouracil and leucovorin in the treatment of advanced colorectal cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2898%2900353-0

7 January 2021

10.1016/S0959-8049(98)00353-0

Identifiers

DOI

1 reference

12 September 2017

1 reference